Whalesbook
Argentina Approves Ceftriaxone for Venus Remedies
Venus Remedies announced Thursday it received marketing authorization from Argentina's national regulatory authority for its antibiotic, Ceftriaxone. This approval marks a significant step for the company in Latin America, expanding its global product portfolio. Ceftriaxone now has marketing authorization in 39 countries.
Expanding Reach in Latin America
The move highlights Venus Remedies' dedication to improving access to vital anti-infective treatments. It also reinforces India's position as a global supplier of quality injectable medicines. Saransh Chaudhary, president of Global Critical Care at Venus Remedies Ltd, called the approval "an important step in strengthening our presence in the region."
Ceftriaxone: A Vital Antibiotic in a Key Market
Argentina is the fourth-largest pharmaceutical market in Latin America, worth about $7.3 billion in 2023. Ceftriaxone is a key antibiotic used to treat serious bacterial infections like meningitis, respiratory tract infections, and surgical infections, making it essential in hospitals. This approval fits the company's strategy to offer clinically important and accessible anti-infective drugs worldwide.
Latin America's Pharmaceutical Market Growth
The overall Latin American pharmaceutical market is forecast to grow significantly, from an estimated nearly $91.85 billion in 2024 to $172.71 billion by 2034. Aditi K Chaudhary, president of International Business, described securing this authorization as a "strategically important milestone in our Latin America expansion journey." In 2024, India exported about $17.5 million in pharmaceutical products to Argentina, and the Latin America and Caribbean region represented 6.69% of India's total pharma exports in FY25.